Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
  • C07D471/14—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
  • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Definitions

• the present invention relates to 9H-pyrrolo [2,3-b: 5,4-c '] dipyridine ⁇ -aza- ⁇ -carbolin derivatives, to their preparation and to their therapeutic application.
• ⁇ -aza- ⁇ -carbolines are defined by the derivatives of 1, 7 diaza carbazole or 8-aza- ⁇ -carboline; in French IUPAC nomenclature (use of ACD / Name 12.00) the name of this tricyclic unit is 9H-pyrrolo [2,3-b: 5,4-c '] dipyridine.
• the present invention relates to compounds acting on protein kinases such as: CHK1, CDK1, CDK2, dyrk2, Flt3, GSK3 beta, MNK2, PDGFR beta, PI3K, PIM1, PIM2, PIM3, PLK, TrkB, all of which are involved in cancer development. More particularly, the present invention relates to compounds acting on a target called Pim involved in the development of cancers.
• Pim kinases encompassing Pim-1, Pim-2 and Pim-3, form a distinct family of serine / threonine kinases, and play a functional role in cell growth, differentiation and apoptosis.
• One of the mechanisms by which Pim kinases can increase cancer cell survival and promote cancer progression is through the modulation of ADB activity, a key regulator of apoptosis.
• Pim kinases are highly homologous to each other and display similar oncogenic behavior.
• Pim kinases particularly Pim-1 and Pim-2, have been found to be abnormally expressed in a large number of hematological malignancies.
• Amson et al. report overexpression of Pim-1 in acute myeloid leukemia and acute lymphoid leukemia, and that overexpression of Pim-1 appears to result from inappropriate activation in various leukemias ⁇ Proc. Natl. Acad. Sci., Vol. 86, 8857-8861 (1989)).
• Studies have demonstrated overexpression of Pim-1 in primary and metastatic CNS lymphoma, an aggressive form of non-Hodgkin lymphoma (Rubenstein et al., Blood, Vol 107, 9, 3716-3723 (2006)). ). Höttmann et al.
• Pim-2 in B-cell chronic lymphocytic leukemia and suggest that upregulation of Pim-2 may be associated with a more aggressive course of the disease (Leukemia, 20, 1774-1782 (2006)).
• Abnormal expression of Pim-1 and Pim-2 has been linked to multiple myeloma (Claudio et al., Blood, v. 100, No. 6, 2175-2186 (2002)).
• Pim-1 Hypermutations of Pim-1 have been identified in diffuse large cell lymphomas (Pasqualucci et al., Nature, Vol 412, 2001, pp. 341-346 (2001)) and in predominantly lymphocytic nodular and nodular Hodgkin's lymphoma. (Liso et al., Blood, Vol 108, No. 3, 1013-1020 (2006)).
• Pim-1 and Pim-2 have been implicated in prostate cancer (Chen et al., Mol Cancer Res, 3 (8) 443-451 (2005)).
• Valdman et al. have demonstrated upregulation of Pim-1 in patients with prostate carcinoma and in high-grade prostatic intraepithelial neoplasia (precancerous lesions) ⁇ The Prostate, (60) 367-371 (2004) ), while Dai et al.
• Pim-2 is linked to the perineural invasion (PNI), during which cancer cells curl around the nerves, which are often found in certain cancers such as cancers of the prostate, pancreas, ducts biliary and head and neck (Ayala et al., Cancer Research, 64, 6082 - 6090 (2004)).
• PNI perineural invasion
• Pim-3 is aberrantly expressed in human and mouse hepatocarcinomas and human pancreatic cancer tissues (Cancer Res. 66 (13), 6741-6747 (2006)).
• Aberrant expression of Pim-3 has also been observed in gastric adenoma and metastatic sites of gastric carcinoma (Zheng et al., J Cancer Res Clin Oncol, 134: 481-488 (2008)).
• Pim kinase inhibitors are useful for the treatment of cancer, including leukemias, lymphomas, myelomas, and various solid tumors, including head and neck cancers, colon cancer, prostate cancer, pancreatic cancer, liver cancer and oral cancer, for example. Since cancer remains a disease for which existing therapies are inadequate, it is clearly necessary to identify new inhibitors of Pim kinases that are effective in the treatment of cancer.
• Patent application WO 2007/044779 describes 9H-pyrrolo [2,3-b: 5,4- c '] dipyridine or ⁇ -aza- ⁇ -carbolines of the following general formula, partially restricted, with respect to the application as published:
• Z and Z2 may also represent C
• - Z1 may finally represent C or N and - R2 may represent a carbon bond or an alkylene radical each may be substituted by many possibilities among which heteroaryloxy, heteroaryl (C1-C5) alkyl, heteroaryl and heterobicycloaryl.
• the preparation process as well as all the examples of this application are limited to derivatives substituted in position 2 and 8 and optionally in position 5.
• B6, B7, B8, B9 may be C or N, but R7 is never heteroaryl.
• the activity of the compounds of this invention is particularly directed to the treatment of cardiac problems.
• the present invention relates to compounds of the following general formula (I):
• R3 is chosen from:
• - R6 is a heteroaryl (5 or 6-membered with 1 to 4 heteroatoms selected from N, S or O) linked to the azacarboline unit either by a C or by an N belonging to R6, R6 being optionally mono or poly substituted; - Ra being obligatorily chosen among:
• heterocycloalkyl is the heterocycloalkyl radical containing at least one nitrogen atom bonded to C (O); and optionally being mono, di or tri substituted;
• Ra and Rs may optionally form a ring substituted by an oxo radical, containing from 4 to 7 chain members, comprising at least one nitrogen atom and optionally another heteroatom selected from N, O and S and optionally substituted by one or more chosen radicals (s) from oxo, F, Cl, Br, I, CF3, CHF2, alkyl, OH, Oalkyl, NO2, NH2, NHAIk or N (Alk) 2 radicals; R3a being selected from:
• Ra and Rs are bonded to the carbon bonds or to Z2, Z3 or Z4 when those represent a carbon chain.
• R3, R6 and Ra are chosen from R2a, R2b or R2c groups chosen independently of one another from:
• the subject of the present invention is thus the compounds as defined above characterized in that the possible substituents of all the substituted groups and groups Rs, R2a, R2b and R2c or the groups are chosen from:
• heterocycloalkyl (C 3 -C 7 ); 10. -NH 2 ;
• R3 is chosen from:
• Alkoxy whose alkyl part is optionally mono, di or tri substituted by R2a, R2b, R2c; 6. -NH 2 , -NH (alkyl), -N (alkyl) 2 whose alkyl part is optionally mono, di or tri substituted by R2a, R2b, R2c;
• Aryl or heteroaryl optionally mono, di or tri substituted by R2a, R2b, R2c;
• R 6 is a heteroaryl (5 or 6-membered with 1 to 4 heteroatoms chosen from N, S or O) bonded to the azacarboline unit, either by a C or by an N belonging to R 6, R 6 being optionally mono or poly substituted with R 2a, R 2b; R2c; - Ra being obligatorily:
• heterocycloalkyl is the heterocycloalkyl radical containing at least one nitrogen atom bonded to C (O); and optionally being mono, di or tri substituted; Rs being selected from the following groups:
• Ra and Rs may optionally form an oxo-substituted ring containing from 5 to 6 members and comprising at least one nitrogen atom and optionally substituted with one or more radicals chosen from oxo, F, CI radicals, Br, I, CF 3, CHF 2, alkyl, OH, Oalkyl, NO 2, NH 2, NHAIk or N (Alk) 2;
• the groups R2a, R2b or R2c are chosen independently of one another from:
• heteroaryl optionally mono or poly substituted with the same or different R3a groups
• heterocycloalkyl optionally mono or poly substituted with the same or different R3a groups
• N alkyl (d-Cio) or cycloalkyl (C 3 -C 7 ) 2 each group being optionally mono or poly substituted with the same or different R 3a groups;
• the possible substituents of the groups R2a, R2b and R2c or the groups R3a are chosen from: 2. F; Cl; Br; I
• heterocycloalkyl (C 3 -C 7 ); 1NH 2 ;
• the subject of the present invention is particularly the products of formula I belonging to the formula la:
• the subject of the present invention is particularly the products of formula I belonging to the formula Ic:
• R6 represents a pyridyl radical optionally mono or poly substituted by one or more radicals Rp identical or different chosen from radicals F, Cl , Br, I, CF3, CHF2, alkyl, OH, Oalkyl, NO2, NH2, NHAIk or N (Alk) 2 and R3 and Ra have any of the meanings indicated above, said products of formula (I) being in all the possible racemic, enantiomeric and diastereoisomeric isomeric forms, as well as addition salts with inorganic and organic acids or with the inorganic and organic bases of said products of formula (I).
• the subject of the present invention is particularly the products of formula I belonging to the formula Id:
• R6 represents a pyrazolyl radical optionally mono or poly substituted by one or more radicals Rp identical or different chosen from radicals F, Cl, Br, I, CF3, CHF2, alkyl, OH, Oalkyl, NO2, NH2, NHAIk or N (Alk) 2 and R3 and Ra have any of the meanings indicated above, said products of formula (I) being all possible racemic isomeric forms, enantiomers and diastereoisomers, as well as addition salts with mineral and organic acids or with the inorganic and organic bases of said products of formula (I).
• alkyl (Ci-Ci 0) alkyl or CRCI 0 means all carbon chains of 1 to 10 carbons, saturated, linear or branched.
• Aryl means phenyl or naphthyl.
• Heteroaryl means all aromatic 5- or 6-membered aromatic monocycles having at least one heteroatom (N, O, S) in particular: pyridine, pyrimidine, imidazole, pyrazole, triazole, thiophene, furan, thiazole, oxazole, and the like.
• aromatic bicyclic systems having at least one heteroatom (N, O, S), especially indole, benzimidazole, azaindole, benzofuran, benzothiophene, quinoloin, tetrazole
• Heterocycloalkyl means all unicyclic monocycles and bicycles (spiro or non-aromatic) having at least one heteroatom (N, O, S at the different possible oxidation states) with or without unsaturation, in particular: morpholine, piperazine, piperidine, pyrrolidine, oxetane, epoxide, dioxane, imidazolone, imidazolinedione, 7-oxa-bicyclo [2.2.1] heptane, azetidine, azepine, hexahydropyrrolo [3,4-b] pyrrole, hexahydropyrrolo [2,3-b] pyrrole, hexahydropyrrolo [3,4- c] pyrrole, hexahydropyrrolo [2,3-c] pyrrole, 2,7- diazaspiro [4.4] nonane, 2,6-diazaspiro [4,4]
• Cycloalkyl (C 3 -C 7 ) means all non-aromatic rings consisting solely of carbon atoms, especially cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane; but may also carry unsaturation, for example cyclopentene, cyclohexene, cycloheptene, bicyclo [2.2.1] heptane.
• alkylhydroxy means all carbon chains of 1 to 10 carbons, saturated, linear or branched carrying at least one hydroxyl group (OH).
• - C 1 -C 1 0 alkoxy means all carbon chains of 1 to 10 carbons, saturated, linear or branched in which there is at least one ether function (COC).
• - C 1 -C 1 0 alkylamino means all carbon chains of 1 to 10 carbons, saturated, linear or branched in which there is at least one amine function (primary, secondary or tertiary).
• the compounds of formula (I) can comprise one or more asymmetric carbon atoms. They can therefore exist as enantiomers or diastereoisomers. These enantiomers, diastereoisomers, as well as their mixtures, including the racemic mixtures, form part of the invention.
• the compounds of formula (I) may comprise one or more E / Z type stereochemies on double bonds or cis / trans bonds on nonaromatic rings. These different stereoisomers and their mixtures are part of the invention.
• the compounds of formula (I) may exist in the form of bases or addition salts with acids. Such addition salts are part of the invention. These salts can be prepared with pharmaceutically acceptable acids
• the compounds of formula (I) may comprise one or more isotopes of the atoms described above, especially deuterium D, tritium T, 11 C, 13 C and 14 C, and
• the strategy is synthesis of the tricyclic nucleus is based on two coupling reactions; a carbon-carbon bond is first created between two suitably selected pyridines, leading to the intermediates of formula Bn, and then the formation of an intramolecular carbon-nitrogen bond leads to the 9H- pyrrolo [2,3-b: 5,4-c '] dipyridine (intermediate of formula Cn see scheme 1 below).
• the present invention also relates to any synthesis method known to those skilled in the art for preparing the products of formula (I) as defined above.
• the subject of the present invention is in particular a general process for the synthesis of the products of formula (I) as defined above, described below in the general scheme: Coupling (Stille, Suzuki)
• the subject of the present invention is in particular a process for synthesizing the products of formula (Ia) as defined above, described hereinafter in Scheme 1.
• the process for preparing the compounds having a (3'-pyridinyl) unit at the 6-position according to the invention consists in a first step in preparing 5-chloro-4- (trimethylstannanyl) -2,3'-bipyridine A1 from 2- (3'-pyridyl) -5-chloropyridine (Journal of the Chemical Society, Perkin Transactions 1 2002, (16), 1847-1849) (Scheme 2)
• the tricyclic unit (C1-type intermediate) is obtained by an intramolecular aryl amination reaction catalyzed by either a palladium complex or copper (I) iodide (scheme 4).
• Diagram 6 The present invention thus relates in particular to a method for synthesizing the products of formula (Ib) as defined above, described in Scheme 6.
• the present invention thus particularly relates to a process for synthesizing the products of formula (Ic) as defined above, described in Scheme 7.
• the boronic reagent, with the carboxamido function can also be prepared before condensation as for a commercial derivative.
• the pattern (1'-methyl-1 ⁇ -pyrazol-4'-yl) is installed by a three-step sequence comprising: a demethylation reaction (C7 ⁇ C8), the formation of a triflate derivative (C8 ⁇ C9) and a Suzuki coupling reaction (C9 ⁇ C10) (scheme 10):
• Figure 1 1 The subject of the present invention is therefore a process for synthesizing the products of formula (Id) as defined above, described in scheme 11.
• the first step is the preparation of 2,5-dichloro-4- (trimethylstannanyl) -pyridine A3 by a method similar to that described above.
• the coupling of Stille (A3 ⁇ B3) with a 2-amino-3- (bromo or iodo) -pyridine derivative substituted in the 5-position is in this case followed by an intramolecular aryl amination reaction (B3 ⁇ C12). , catalyzed by a copper salt at the degree of oxidation (I) or (II) (diagram 12):
• the functionalization of the position 4 is done by the same sequence (C1 ⁇ C2 ⁇ C3 ⁇ C6) as for the compounds bearing a 3'-pyridyl group (diagram 13).
• the present invention thus relates in particular to a process for the synthesis of the products of formula (Id) as defined above, described in Scheme 14.
• alkoxy group at position 3 is carried out from the derivative 3-bromo-6- (pyridin-3-yl) -9H-pyrrolo [2,3-b: 5,4-c '] dipyridine obtained by the action of dibroma in acetic acid on 6- (pyridin-3-yl) -9H-pyrrolo [2,3-b: 5,4-c] dipyridine.
• a methoxy or ethoxymethoxy unit may be introduced in the presence of copper (I) iodide (scheme 15).
• the subject of the present invention is also, as medicaments, the products of formula (I) as defined above, as well as their prodrugs, said products of formula (I) being in all the possible isomeric forms racemic, enantiomers and diastereoiso isomers, as well as addition salts with inorganic and organic acids or with the pharmaceutically acceptable mineral and organic bases of said products of formula (I).
• the subject of the present invention is, in particular, as medicaments the products of formula (I) as defined above, whose names follow:
• the present invention also relates to pharmaceutical compositions containing as active ingredient, a compound according to any one of the preceding claims and at least one pharmaceutically compatible excipient.
• the present invention also relates to the pharmaceutical compositions according to the preceding claim used for the treatment of cancer.
• the present invention relates to pharmaceutical compositions comprising, as active principle, a compound according to the invention.
• These pharmaceutical compositions contain an effective dose at least one compound according to the invention, or a pharmaceutically acceptable salt, of said compound, as well as at least one pharmaceutically acceptable excipient.
• excipients are chosen according to the pharmaceutical form and the desired mode of administration from the usual excipients which are known to those skilled in the art.
• compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous administration may be administered in unit dosage form. administration, in admixture with conventional pharmaceutical excipients, to animals and humans for the treatment of the above disorders or diseases.
• Suitable unit dosage forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, subcutaneous, intramuscular forms of administration. or intravenous.
• Pim kinase inhibitors of the present invention are useful for the treatment of cancer. Since cancer remains a disease for which existing therapies are inadequate, it is clearly necessary to identify new inhibitors of Pim kinases that are effective in the treatment of cancer.
• the present invention also relates to a method of treatment of the pathologies indicated above which comprises the administration to a patient of an effective dose of a compound according to the invention, or one of pharmaceutically acceptable salts thereof.
• R and R4 are as defined in the general scheme Examples 2, 3, 4, 5, 6, 8, 18, 30, 31, 32, 33, 34, 35, 36, 40, 41, 42, 43 , 93, 94, 95, 96, 97, 98, 1, 10, 11, 1, 15, 116, 1, 17, 118, 19 are the intermediates of Cn
• R, R3, R4 and GP have the definitions indicated in the general scheme.
• R Cl, -OMe, -OH, -OSO 2 CF 3
• R 4 H, I, -OMe, -OH, -OSO 2 CF 3 ,
• One particular object of the present invention is, as new industrial products, the synthesis intermediates of the products of formula (I) described in the above general schemes and 1 to 15.
• One particular object of the present invention is, as new industrial products, the synthesis intermediates of the products of formula An described in the above diagrams:
• One particular object of the present invention is, as new industrial products, the intermediates for the synthesis of the products of formula Bn described in the above schemes:
• the object of the present invention is therefore, as new industrial products, the Intermediates of synthesis of the products of formula C n described in the diagrams above:
• DAD wavelength scanning detector
• HATU O- (7-Azabenzotriazol-1-yl) -N, N, N ', N'-tetra-methyluronium hexafluorophosphate
• LiTMP lithium amide of 2,2,6,6-tetramethylpiperidine MS: mass spectrometry THF: tetrahydrofuran Tr: retention time
• the dilution solvents are dimethylsulfoxide; methanol; acetonitrile; dichloromethane.
• the reaction medium is treated with a 10% aqueous solution of sodium hydrogencarbonate and then diluted with ethyl acetate. After decantation, the aqueous phase is extracted twice with ethyl acetate.
• the deposit is purified by chromatography on a silica column, eluting with a 98/2 to 92/8 dichloromethane / methanol mixture to give 6.5 g of 3-fluoro-6- (pyridin-3-yl). ) -9H-pyrrolo [2,3-b: 5,4-c '] dipyridine as a brown solid.
• the aqueous phase is extracted twice with ethyl acetate.
• the combined organic phases are washed with water and then dried over anhydrous magnesium sulphate, filtered and concentrated under reduced pressure.
• the residue is purified by chromatography on a silica column, eluting with a dichloromethane / methanol mixture 100/0 to 95/5 to give 4.75 g of 3-fluoro-9 - [(4-methylphenyl) sulfonyl] -6- ( pyridin-3-yl) -9H-pyrrolo [2,3-b: 5,4-c '] dipyridine.
• Example 7 4- [3-Fluoro-6- (pyridin-3-yl) -9H-pyrrolo [2,3-b: 5,4-c] dipyridin-4-yl] -N- (4-methylpiperazine) -1-yl) benzamide
• the deposit is concentrated under reduced pressure and is then purified by chromatography on a silica column, eluting with a dichloromethane / methanol mixture 98/2 to 90/10 to give 34 mg of 4- [3-fluoro-6- (pyridin-3- yl) -9H-pyrrolo [2,3-b: 5,4-c] dipyridin-4-yl] -N- (4-methylpiperazin-1-yl) benzamide.
• reaction mixture is filtered and then poured on 100 ml of water and 250 ml of ethyl acetate with vigorous stirring. After decantation, the aqueous phase is extracted with 100 ml of ethyl acetate and the combined organic phases are dried over magnesium sulfate, filtered and then evaporated under reduced pressure. The residue is purified by chromatography on a silica column, eluting with a dichloromethane / methanol / aqueous ammonia mixture at 28% 100/0/0 at 90/10 / 0.2; the product is suspended in 15 ml of ethyl acetate.
• Example 10 is obtained from 150 mg of 3-fluoro-4-iodo-6- (pyridin-3-yl) -9H-pyrrolo [2,3-b: 5 4-c '] dipyridine and 383 mg N- (3-dimethylaminopropyl) -4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzamide.
• reaction mixture After cooling, the reaction mixture is diluted with 6 ml of 1,4-dioxane, 2 ml of methanol and 0.1 ml of trifluoroacetic acid and then treated with 150 mg of propanethiol-type resin grafted onto silica for 4 hours at room temperature. .
• the reaction mixture is filtered and then washed twice with a 4/1 4-dioxane / methanol mixture. After evaporation under reduced pressure, the residue is dissolved in 2 ml of dimethylformamide and 0.1 ml of trifluoroacetic acid, filtered and then purified by preparative HPLC.
• Example 18 4- [3-Fluoro-6- (pyridin-3-yl) -9H-pyrrolo [2,3-b: 5,4-c] dipyridin-4-yl] benzoyl chloride
• a mixture of 10 g of 5-chloro-2-methoxypyridine and 220 ml of tetrahydrofuran is cooled to -78 ° C. and a freshly prepared solution is then added progressively from 14.1 ml of 2,2,6,6-tetramethylpiperidine. in 50 ml of tetrahydrofuran and 36.4 ml of 2.3 N n-butyllithium in hexane. After stirring for 4 h at -78 ° C., 17.3 g of trimethyltin chloride dissolved in 30 ml of tetrahydrofuran are added to the reaction mixture.
• reaction mixture is stirred at ambient temperature for 18 h and then treated with 200 ml of water and 200 ml of 10% aqueous ammonium chloride solution and extracted with 500 ml and then 200 ml of ethyl acetate.
• the combined organic phases are dried over magnesium sulphate, filtered and then concentrated to dryness under reduced pressure.
• the residue is purified by chromatography on a silica column eluting with dichloromethane to give 17.7 g of 5-chloro-2-methoxy-4- (trimethylstannanyl) pyridine A2 in the form of a colorless oil.
• the reaction mixture is hydrolyzed with a mixture of 200 ml of 10% aqueous sodium hydrogen carbonate solution and 100 ml of water and is then extracted twice with 200 ml of ethyl acetate.
• the reaction mixture is diluted with 50 ml of ethyl acetate and washed with 50 ml of water. After decantation, the aqueous phase is extracted with 100 ml of ethyl acetate and the organic phases are combined, dried over magnesium sulfate, filtered and concentrated in vacuo. The residue is purified by chromatography on a silica column eluting with ethyl acetate to give 168 mg of 3-fluoro-6- (1-methyl-1H-pyrazol-4-yl) -9H-pyrrolo [ 2,3-b: 5,4-c '] dipyridine as a yellow solid.
• the white solid obtained is purified by chromatography on a silica column eluting with ethyl acetate to give 225 mg of 3-fluoro-9 - [(4-methylphenyl) sulfonyl] -6- (1-methyl-1 H-pyrazol-4-yl) -9H-pyrrolo [2,3-b: 5,4-c '] dipyridine as a white solid.
• Example 37 From 55 mg of product of Example 36 are obtained 35 mg of N- [2- (dimethylamino) propyl] -4- [3-fluoro-6- (1-methyl) -1H-pyrazol-4-yl) -9H-pyrrolo [2,3-b: 5,4-c] dipyridin-4-yl] benzamide as a pale yellow solid.
• reaction mixture is filtered on celite, rinsed with 10 ml of ethyl acetate and then washed twice with 10 ml of water. After decantation, the organic phase is dried over magnesium sulfate, filtered and then concentrated to dryness under reduced pressure. The residue is purified by chromatography on a silica column eluting with a heptane / ethyl acetate mixture: 50/50 to 0/100 to give 125 mg of 5'-chloro-2 ', 4-dimethoxy-3,4' bipyridin-2-amine in the form of a white solid.
• the aqueous phase is extracted with 200 ml of ethyl acetate and the organic phases are combined and concentrated in vacuo.
• the residue is taken up in a mixture of 100 ml of 80/20 dichloromethane: ethyl acetate mixture, supplemented with 6.0 g of silica and concentrated under reduced pressure.
• the solid deposit formed is purified by chromatography on a silica column, eluting with a dichloromethane / ethyl acetate mixture 100/0 to 80/20 to give 124 mg of 9H-pyrrolo [2,3-b: bis (trifluoromethanesulphonate): 5,4-c '] dipyridine-4,6-diyl as a rust solid.
• Example 43 4- (4 - ⁇ [2- (Dimethylamino) ethyl] carbamoyl ⁇ phenyl) -9H-pyrrolo [2,3-b: 5,4-c] dipyridin-6-yl trifluoromethanesulfonate
• the aqueous phase is extracted with 10 ml of ethyl acetate and the organic phases are combined, dried over magnesium sulfate, filtered and concentrated in vacuo. The residue is taken up in a mixture of 30 ml of dichloromethane / methanol 90: 10, supplemented with 600 mg of silica and concentrated under reduced pressure.
• the solid deposit formed is purified by chromatography on a silica column, eluting with a dichloromethane / methanol mixture 100/0 to 90/10 to give 56 mg of 4- (4 - ⁇ [2- (dimethylamino) ethyl] carbamoyl trifluoromethanesulphonate ⁇ phenyl) -9H-pyrrolo [2,3-b: 5,4-c '] dipyridin-6-yl as a beige solid.
• 2-Trifluoromethyl-propan-1,2-diamine is prepared in a racemic manner following the synthesis described in J.Org.Chem. 2006, 71 (18), 7075-7079.
• the optically pure alpha-methyl-benzylamine used in the publication is just replaced by benzylamine in the first step of the process. The rest of the synthesis proceeds according to the publication.
• the mixture is left between 30 minutes and 2 hours with stirring, if the reaction is incomplete after 2 hours, it can also be heated for 30 minutes under microwave at 140 ° C.
• the pyridine is then evaporated under reduced pressure.
• the residue is dissolved in a CH 2 Cl 2 ZMeOH mixture and 500 mg of silica are added.
• the solvents are evaporated off under reduced pressure and the product is recovered by chromatography on silica gel (eluent: CH 2 Cl 2 / MeOH or CH 2 Cl 2 / NH 3 2N in MeOH: gradient from 100/0 to 85/15).
• the reaction is carried out in 4 passes of approximately 1.5 g in a 20 ml Vial Biotage reactor and in the Biotage microwave oven.
• a suspension of 4.2 g (16.27 mmol) of 2 ', 5'-dichloro-5-fluoro [3,4'] bipyridinyl-2-ylamine, 7 g (48.81 mmol) of potassium carbonate and 0.62 g (3.25 mmol) of copper iodide in 100 ml of dimethylsulfoxide is heated in an oil bath at 170 ° C. for 3 h 30 min.
• the reaction mixture is then stirred in 300 g of ice and 250 ml of 28% aqueous ammonia solution for 1 hour and then extracted with 5 times 300 ml of ethyl acetate.
• 6-Chloro-3-fluoro-9H-dipyrido [2,3-b: 4 ', 3'-d] pyrrole 93 (800 mg, 3.6 mmol) is dissolved in 20 mL of DMF in a dry monocolon and under argon (a slight heating to 35 ° C may be necessary in some cases for complete dissolution).
• Sodium hydride (245 mg, 6.1 mmol, 1.7 eq.) Is added all at once, and then the reaction mixture is stirred under an inert atmosphere for 3 hours.
• the tosyl chloride dissolved in 2 ml of DMF is then added (duration of introduction about two minutes).
• the reaction medium is poured into a mixture of an aqueous solution of 10% NaHCO 3 (50 ml) and water (30 ml).
• the precipitate is filtered and then filtered with 50 mL of water.
• the precipitate is purified by chromatography on silica gel (no need to swab on silica the product is sufficiently soluble in dichloromethane 70 g SiO2, CH2Cl2 / AcOEt: 100/0 to 90/10).
• reaction medium After stirring for 30 minutes at -78 ° C., the reaction medium is poured into a mixture of ethyl acetate (150 ml) and a half-saturated aqueous ammonium chloride solution (50 ml of NH 4 Cl 2). saturated + 50 mL of water). The phases are separated, and then the organic phase is washed with an aqueous solution of sodium thiosulfate 5%. The organic phase is dried over MgSO 4, filtered and then evaporated under reduced pressure.
• reaction mixture is diluted with 50 ml of ethyl acetate and washed with 50 ml of water. After decantation, the aqueous phase is extracted with 100 ml of ethyl acetate and the organic phases are combined, dried over magnesium sulfate, filtered and concentrated in vacuo. The residue is purified by chromatography on a silica column (eluent: CH 2 Cl 2 ZMeOH 100/0 to 95/5).
• the reaction medium is hydrolyzed with 100 ml of water and this is then extracted twice with 250 ml. of ethyl acetate. The organic phases are combined, dried over sodium sulphate, filtered and concentrated to dryness under reduced pressure. The residue is then taken up in a mixture of tetrahydrofuran (2.5 ml) and methanol (2.5 ml), then 2.5 ml of aqueous 2N lithium hydroxide solution are added. After total disappearance of the starting material, water is added to the reaction medium and the pH is reduced to 4 by addition of an aqueous solution of hydrochloric acid. The precipitate formed is isolated by filtration, rinsed with distilled water, drained and dried under vacuum.
• reaction medium After cooling, the reaction medium is treated with a 10% aqueous solution of sodium hydrogencarbonate and then diluted with ethyl acetate. After decantation, the aqueous phase is extracted twice with ethyl acetate. The combined organic phases are dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure. The residue is taken up in a mixture of dichloromethane and methanol and is then filtered to give 1.9 g (51%) of 5'-chloro-3,2 ': 4', 3 "-terpyridin-2" -amine 114 in the form of a light beige solid which will be used without further purification in the next step.
• reaction medium After stirring for 30 minutes at -78 ° C., the reaction medium is poured into a mixture of ethyl acetate (50 ml) and a half-saturated aqueous ammonium chloride solution (30 ml of NH 4 Cl 2). saturated + 30 ml of water). The phases are separated, and then the organic phase is washed with an aqueous solution of sodium thiosulfate 5%. The organic phase is dried over MgSO 4, filtered and then evaporated under reduced pressure.
• 6-Chloro-3- (2-methoxyethoxy) -4-iodo-9- (toluene-4-sulfonyl) -dipyrido [2,3-b: 4 ', 3'-d] pyrrole (85 mg, 0, 14 mmol) is dissolved in 1.5 mL of THF and 1.5 mL of MeOH.
• the aqueous phase is extracted with 30 ml of ethyl acetate and the combined organic phases are dried over magnesium sulfate, filtered and then evaporated under reduced pressure.
• the residue is purified by chromatography on a silica column (eluent CH 2 Cl 2 / 2N NH 3 in MeOH: 100/0 to 90/10) to give 30 mg of N- [2- (dimethylamino) ethyl] -4- [3- (2 methoxyethoxy) -6- (pyridin-3-yl) -9H-pyrrolo [2,3-b: 5,4-c] dipyridin-4-yl] benzamide.
• Excipient for a tablet finished at 1 g (detail of the excipient: lactose, talc, starch, magnesium stearate).
• Examples 44 and 87 are taken as examples of pharmaceutical preparation, this preparation can be carried out if desired with other products examples in the present application.
• the pharmacological properties of the compounds of the invention can be confirmed by a number of pharmacological assays.
• the following examples of pharmacological assays were carried out with compounds according to the invention.
• the compounds of the invention are tested according to a TR-FRET assay ("Time Resolved-Fluorescence Resonance Energy Transfer", fluorescence energy transfer by resonance in time. resolved) in vitro used routinely.
• TR-FRET assay is based on the detection of phosphorylation of the Ser1 12 specific residue in the Bad protein, which has been shown to be a natural substrate of Pim kinases in cells.
• the following reagents are used: Hisim-tagged recombinant full-length human Pim-protein, Pim-1, Pim-2, or Pim-3 (prepared according to J. Mol., Biol.
• the assay is based on PerkinElmer's LANCE TM technology: the Eu-labeled antibody binds to phospho-Ser1 12 and generates a TR-FRET signal by interaction with PCA-labeled His6 antibody bound to His6 tag of Bad.
• the fluorescence signal ratio at 665 nm on fluorescence signal at 615 nm is used as the signal reading for Cl 50 (calculations based on the 4-parameter logistic model).
• the assay is implemented in a 384-well format; liquid handling is carried out using a Beckman 3000 liquid handling station.
• the compounds under test are tested at 10 concentration points in duplicate; the highest compound concentration is typically 30 ⁇ M.
• the concentration of ATP is equal to 40 ⁇ M.
• Representative compounds of the invention are also screened for their effects on cell proliferation and viability using a variety of tumor cell lines from humans, representative of various pathological indications. These cell lines include:
• TF-1 acute myelogenous leukemia, AML M6 at the time of diagnosis
• KG-1 erythroleukemia evolving in AML
• KG-Ia AML, subclone derived from immature KG-1
• EOL-1 AML, eosinophilic leukemia
• HL-60 (AML, M3); Kasumi-1 (AML);
• K-562 CML - chronic myelogenous leukemia, blast crisis
• JURL-MK1 CML blast crisis
• T-ALL T-cell acute lymphoblastic leukemia
• Jurkat T-ALL
• NALM-6 B-ALL-ALL to B-cells
• Jeko-1 B-NHL - B-cell non-Hodgkin's lymphoma, large cell variant leukemia-derived mantle cell lymphoma
• WSU-DLCL2 B-NHL, diffuse large B-cell lymphoma
• RPMI-8226 MM - multiple myeloma
• JVM-2 B-CLL - B-cell chronic lymphocytic leukemia
• JVM-3 (B-CLL).
• HCT-116 colon cancer
• HT-29 colon cancer
• HC-15 colon cancer
• H460 lung cancer, non-small cell lung cancer
• B16F10 (melanoma); MDA-A1 (breast cancer);
• MDA-MB231 (breast cancer)
• MDA-MB231 adr breast cancer
• PANC-1 pancreatic cancer
• PC-3 prostate cancer
• the tumor cells are incubated in a 96-well or 384-well format for 48, 72 or 96 hours, preferably 72 hours, with a compound of the invention at 3-fold dilutions with in general, nine doses in total, the highest dose being equal to 10 ⁇ M or 30 ⁇ M.
• Cell viability is assessed by adding CelITiter-Blue ® (Promega, Madison, Wisconsin, USA) for 4 hours and end point readings are performed using a SpectraMax Genmini EM plate reader (Molecular Devices, Sunnyvale , California, United States).
• the CelITiter-Blue ® cell viability assay measures the ability of cultured cells to effect reduction of resazurin to resorufin, wherein the intensity of the fluorescence signal is directly proportional to the number of living cells.
• EC 50 represents the concentration of compound that leads to a 50% reduction in proliferative cell viability / expansion.
• Example 3 The activity of the molecules is evaluated on the JEKO cell line or DND-41 by measuring the level of phosphorylation of Bad and the total Bad rate, and this, by the Elisa technique.
• the JEKO or DND-41 cells are resuspended at a concentration of 500,000 cells per ml.
• the cells are then diluted in RPMI-1640 medium containing 20% fetal calf serum. 225 ⁇ l of cells are placed in a plate.
• the serial dilutions of the molecules are then carried out (8 points, dilution to 1/3, start of range to 10 mM). Each dilution point is then diluted 1/100 in medium.
• 25 .mu.l of each of the concentrations are added to the cells and then incubated for 3 hours at 37.degree. 100 ⁇ l of the cells are transferred to a poly-D-Lysine treated plate. The plate is then incubated for 5-10 minutes at 37 ° C.
• washing buffer 100 ⁇ l of quenching buffer are added and then incubated for 15 minutes at room temperature. After washing, 100 ⁇ l of stop buffer are added followed by incubation for 1 hour at room temperature. After washing, 50 ⁇ l of the primary antibody diluted to 1/250 for pBAD (CeII Signaling Cat # 5284) and 1/500 for Bad (MBL Cat # 591) are added to each of the plates. Each of the plates is incubated for 2 hours at room temperature.
• Class B IC50 between 100 nM and 1000 nM (or 1 ⁇ M)
• Class C IC50 between 1 ⁇ M and 5 ⁇ M
• Class D IC50 greater than 5 ⁇ M
• the cell proliferation results are expressed according to the following classification:
• Class A EC50 or IC50 less than 100 nM
• Class B EC50 or IC50 between 100 nM and 1000 nM (or 1 ⁇ M)
• Class C EC50 or IC50 between 1 ⁇ M and 5 ⁇ M

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=42101692

Family Applications (1)

Country Status (16)

Families Citing this family (9)

Family Cites Families (7)

• 2009
  • 2009-11-30 KR KR1020117024857A patent/KR20110130504A/ko not_active Application Discontinuation
  • 2009-11-30 RU RU2011142791/04A patent/RU2011142791A/ru not_active Application Discontinuation
  • 2009-11-30 US US13/258,924 patent/US20120208809A1/en not_active Abandoned
  • 2009-11-30 UY UY0001032275A patent/UY32275A/es not_active Application Discontinuation
  • 2009-11-30 SG SG2011068889A patent/SG174903A1/en unknown
  • 2009-11-30 EP EP09797115A patent/EP2411389A2/de not_active Withdrawn
  • 2009-11-30 WO PCT/FR2009/052330 patent/WO2010109084A2/fr active Application Filing
  • 2009-11-30 AU AU2009342734A patent/AU2009342734A1/en not_active Abandoned
  • 2009-11-30 CN CN2009801583033A patent/CN102365282A/zh active Pending
  • 2009-11-30 AR ARP090104599A patent/AR073431A1/es unknown
  • 2009-11-30 TW TW098140843A patent/TW201035097A/zh unknown
  • 2009-11-30 BR BRPI0924844A patent/BRPI0924844A2/pt not_active IP Right Cessation
  • 2009-11-30 MX MX2011010062A patent/MX2011010062A/es not_active Application Discontinuation
  • 2009-11-30 CA CA2756152A patent/CA2756152A1/fr not_active Abandoned
  • 2009-11-30 JP JP2012501334A patent/JP2012521394A/ja active Pending
• 2011
  • 2011-09-21 IL IL215286A patent/IL215286A0/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events